Venetoclax for relapsed/refractory CLL will be considered at the next Pharmaceutical Benefits Advisory Committee (PBAC) meeting in March, 2017 for consideration for inclusion on the Pharmaceutical Benefits Scheme. (PBS)
Patients, family members, health care organisations, clinicians, researchers and other stakeholders are welcome to provide feedback to PBAC via their online portal.
Please don’t underestimate the value of your feedback.
NOTE: The CLOSING date is next Wednesday 8th of February, 2017
Thanks to Sharon Winton, CEO, Lymphoma Australia for bringing this to my attention.